Prediction of complete pathologic response to veliparib/carboplatin plus standard neoadjuvant therapy in HER2 negative breast cancer: Exploratory protein pathway marker results from the I-SPY 2 trial

被引：2
|
作者：
Wulfkuhle, J. D.
Yau, C.
Wolf, D. M.
Gallagher, R. I.
Deng, J.
Brown-Swigart, L.
Hirst, G.
Rugo, H.
Olopade, O. I.
Esserman, L.
Berry, D.
van't Veer, L.
Petricoin, E. F.
机构：
[1] George Mason Univ, Manassas, VA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] QuantamLeap Healthcare Collaborat, Berkeley, CA USA
[4] Univ Chicago, Chicago, IL 60637 USA
[5] Berry Consultants LLC, Austin, TX USA
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P3-07-48
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-07-48
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Predictors of pathologic complete response in HER2 positive breast cancer patients treated with neoadjuvant targeted therapy
    Rosario, Mariela Huerta
    Sahoo, Sunati
    CANCER RESEARCH, 2020, 80 (04)
  • [22] Tumor infiltrating lymphocytes as a predictor of pathologic complete response to neoadjuvant therapy in HER2 positive breast cancer
    Chargoy, Alberto Monroy
    Verduzco-Aguirre, Haydee Cristina
    Chargoy, Javier Monroy
    Espinosa-Fernandez, Jose Rodrigo
    Ojeda, Jesus Antonio Martinez
    Cabrera-Galeana, Paula
    CANCER RESEARCH, 2024, 84 (09)
  • [23] Impact of body mass index on pathological complete response after neoadjuvant chemotherapy: Results from the I-SPY 2 trial
    Wang, Haiyun
    Yee, Douglas
    Potter, David
    Jewett, Patricia
    Yau, Christina
    Beckwith, Heather
    Watson, Allison
    O'Grady, Nicholas G.
    Wilson, Amy
    Brain, Susie
    Blaes, Anne
    CANCER RESEARCH, 2021, 81 (04)
  • [24] Evaluation of Tucatinib plus (Paclitaxel plus Pertuzumab plus Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL
    Potter, David A.
    Roesch, Erin
    Yau, Christina
    Lu, Ruixiao
    Wolf, Denise
    Samson, Susan
    Stafford, Debra
    Albain, Kathy S.
    Isaacs, Claudine
    Trivedi, Meghana
    Yee, Douglas
    Boughey, Judy
    Thomas, Alexandra
    Chien, A. Jo
    Hylton, Nola
    Li, Wen
    DeMichele, Angela
    Perlmutter, Jane
    Symmans, W. Fraser
    Hershman, Dawn L.
    Melisko, Michelle
    Veer, Laura J. van ' t
    Wilson, Amy
    Asare, Smita M.
    Berry, Donald A.
    Schwab, Richard
    Rugo, Hope S.
    Esserman, Laura J.
    CANCER RESEARCH, 2022, 82 (04)
  • [25] Characterizing the biology and response of locally advanced breast cancer in women undergoing neoadjuvant therapy: preliminary results from the I-SPY trial
    Hylton, N.
    Carey, L.
    DeMichele, A.
    Blume, J.
    Broadwater, G.
    Madhavan, S.
    Rosen, M.
    George, S.
    Esserman, L.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S22 - S22
  • [26] Clinical examination and breast MRI as predictors of pathologic complete response post neoadjuvant therapy in HER2 overexpressed subtypes and triple negative breast cancer
    Andrade, F. E. M.
    De Barros, A. C. S.
    Docema, M. F.
    Heinzen, R. N.
    De Andrade, J. Z.
    Nimir, C.
    Mano, M. D. S.
    Gianotti, D.
    Ribeiro, K. D. C. B.
    CANCER RESEARCH, 2017, 77
  • [27] Efficacy of T-DM1+pertuzumab over standard therapy for HER2+breast cancer: Results from the neoadjuvant I -SPY 2 TRIAL
    DeMichele, Angela M.
    Moulder, Stacy
    Buxton, Meredith
    Yee, Douglas
    Wallace, Anne
    Chien, Jo
    Isaacs, Claudine
    Albain, Kathy
    Boughey, Judy
    Kemmer, Kathleen
    Haley, Barbara
    Lang, Julie
    Kaplan, Henry
    Minton, Susan
    Forero, Andres
    Elias, Anthony
    Nanda, Rita
    Korde, Larissa
    Schwab, Richard
    Melisko, Michelle
    Sanil, Ashish
    Hogarth, Michael
    Hylton, Nola
    Paoloni, Melissa
    Symmans, Fraser
    Perlmutter, Jane
    Lyandres, Julia
    Yau, Christina
    Berry, Don
    Esserman, Laura
    CANCER RESEARCH, 2016, 76
  • [28] Application of machine learning to elucidate the biology predicting response in the I-SPY 2 neoadjuvant breast cancer trial
    Sayaman, Rosalyn W.
    Wolf, Denise M.
    Yau, Christina
    Wulfkuhle, Julie
    Petricoin, Emanuel
    Brown-Swigart, Lamorna
    Asare, Smita M.
    Hirst, Gillian L.
    Sit, Laura
    O'Grady, Nicholas
    Hedistian, Diane
    Esserman, Laura J.
    LaBarge, Mark A.
    van't Veer, Laura J.
    CANCER RESEARCH, 2020, 80 (04)
  • [29] Immunohistochemical Status Predicts Pathologic Complete Response to Neoadjuvant Therapy in HER2 Overexpressing Breast Cancers
    Winer, Leah
    Ruth, Karen
    Nagarathinam, Rajeswari
    McShane, Melissa
    Porpiglia, Andrea S.
    Pronovost, Mary
    Aggon, Allison
    Bleicher, Richard J.
    Williams, Austin
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S92 - S92
  • [30] Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
    Beckwith, Heather
    Schwab, Richard
    Yau, Christina
    Stringer-Reasor, Erica
    Wei, Shi
    Chien, A. Jo
    Albain, Kathy S.
    Kalinsky, Kevin
    Wallace, Anne
    Elias, Anthony
    Yee, Douglas
    Clark, Amy S.
    Boughey, Judy C.
    Han, Heather
    Nanda, Rita
    Isaacs, Claudine
    Mitri, Zahi
    Lang, Julie E.
    Thomas, Alexandra
    Sanft, Tara
    DeMichele, Angela
    Perlmutter, Jane
    Rugo, Hope S.
    Hylton, Nola M.
    Symmans, W. Fraser
    Melisko, Michelle E.
    van't Veer, Laura J.
    Wilson, Amy
    Asare, Smita M.
    Sanil, Ashish
    Berry, Donald A.
    Esserman, Laura J.
    CANCER RESEARCH, 2021, 81 (04)
12345